Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 31
Phase 41

Trial Status

Recruiting1
Other3

Role Distribution

Principal Investigator4
PI Rate100%

Activity Timeline

Clinical Trials (4)

NCT07231939Recruiting
Use of Flozins (Empagliflozin/Dapagliflozin) for Prevention of AKI
Acute Kidney InjuryContrast-Induced Acute Kidney InjuryCoronary Artery Disease+1 more
PrincipalinvestigatorStart date: 2025-11-01
NCT05905965Phase 3Unknown
Efficacy of Double vs Standard Empapagliflozin Dose for METabolic syndromE tReatment
Metabolic Syndrome
PrincipalinvestigatorStart date: 2023-05-01
Determinants of the Level of Anti-SARS-CoV-2 IgG ANTibodiEs After Vaccination Study
SARS-CoV2 AntibodiesSARS-CoV2 Infection
PrincipalinvestigatorStart date: 2021-04-20
NCT07203846Phase 4Not Yet Recruiting
Modulation of Gut MicroFLORA With Rifaximin to Reduce High Platelet Reactivity in Post-ACS Patients on Ticagrelor
ACS - Acute Coronary SyndromeAnti-Bacterial AgentsBlood Platelets+10 more
Principalinvestigator

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Publications (0)

No publications found for this investigator.

Clinical Trials (4)

Showing 4 of 4 trials

NCT07231939PrincipalInvestigator

Use of Flozins (Empagliflozin/Dapagliflozin) for Prevention of AKI

Acute Kidney InjuryContrast-Induced Acute Kidney InjuryCoronary Artery Disease+1 more
Recruiting
NCT05905965Phase 3PrincipalInvestigator

Efficacy of Double vs Standard Empapagliflozin Dose for METabolic syndromE tReatment

Metabolic Syndrome
Unknown
NCT05109585PrincipalInvestigator

Determinants of the Level of Anti-SARS-CoV-2 IgG ANTibodiEs After Vaccination Study

SARS-CoV2 AntibodiesSARS-CoV2 Infection
Unknown
NCT07203846Phase 4PrincipalInvestigator

Modulation of Gut MicroFLORA With Rifaximin to Reduce High Platelet Reactivity in Post-ACS Patients on Ticagrelor

ACS - Acute Coronary SyndromeAnti-Bacterial AgentsBlood Platelets+10 more
Not Yet Recruiting

All 4 trials loaded